Wednesday, 13 November 2024
  
Login

Australia's most trusted
source of pharma news

Wednesday, 13 November 2024
News

GM therapy passes muster

Posted 29 October 2024 AM

The Office of Gene Technology Regulator (OGTR) has deemed a proposed clinical trial of genetically modified (GM) bacteriophages poses "negligible risks" with a consultation now open to inform its final decision on whether to issue a licence.

The Western Sydney Local Health District applied for a licence to administer GM bacteriophages, alone or in combination with non-GM bacteriophage therapy for the treatment of patients with mycobacterial infections in April before being announced by the regulator in July.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.